Compare Genuine Parts Company (GPC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Novo Nordisk A/S — how do they compare? Genuine Parts Company trades at $127.02 (market cap $17.67B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9.4× Genuine Parts Company's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Novo Nordisk A/S for 116 Days on average.
| GPC | NVO | |
|---|---|---|
Market Cap | $17.67B | $165.31B |
Volume | 1,079,458 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $63.98 |
52-Week Low | $92.47 | $35.29 |
Typical Hold Time | 75 Days | 116 Days |
Enterprise Value | $23.76B | $179.56B |
Dividend Yield | 3.32% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 2.2% on the day, with a bullish technical signal and support near $125. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while revenue grew to $24.3B in 2025. Analyst consensus is a Buy with a $145.75 price target, and the upcoming corporate split into automotive and industrial units in Q1 2027 is a key catalyst.
The outlook is positive due to the spinoff potential and steady dividend, but risks include thin net margins of 0.13% and rising debt-to-asset ratios. Investors should weigh the bullish analyst sentiment against profitability challenges and execution risks from the separation.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
